Bright Green Corporation
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lynn Stockwell
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 401 East Las Olas Boulevard Fort Lauderdale FL United States of America 33301
- IPO Date
- May 17, 2022
- CIK
- 0001886799
- Website
- brightgreen.us
- Similar Companies
- Business
- Bright Green Corporation operates as a producer and manufacturer of plant-based drugs and active pharmaceutical ingredients (APIs), specializing in federally authorized cannabis and cannabis-derived products for medicinal applications. The company's core offerings include legal cannabis, cannabis extracts, tetrahydrocannabinol, and pharmaceutical-grade APIs produced under Good Manufacturing Practices (GMP) and DEA regulations, primarily serving research, manufacturing, export, and medicinal product preparation markets across the United States. Founded in 2019 and headquartered in Grants, New Mexico, Bright Green aims to improve quality of life by advancing medicinal plant-based therapies with a focus on compliance and federal legalization. Bright Green Corporation has recently undergone significant strategic restructuring highlighted by a court-supervised merger with PharmAGRI Capital Partners, which transforms the company into a sovereign pharmaceutical platform integrating its DEA registrations and pharmaceutical assets into PharmAGRI's fully integrated "seed to syringe" infrastructure. This merger includes the appointment of Lynn Stockwell as CEO and Chairwoman, setting a new leadership direction. The company is also strategically partnering with Tesla to deploy up to 10,000 Optimus 3+ humanoid robots across its operations as part of a modernization and automation effort. Bright Green has filed for Chapter 11 bankruptcy reorganization with plans to emerge stronger, backed by federal loan guarantees and substantial investment to secure and expand pharmaceutical production capacity. Additionally, the company plans an initial public offering (IPO) by the end of 2025 to enable broader market access and federal contract execution. Recent capital commitments and debt financing initiatives aim to advance commercialization and DEA compliance efforts at its production facilities. This evolution situates Bright Green Corporation within the pharmaceutical and federally regulated cannabis industries, serving clients ranging from medical researchers to pharmaceutical manufacturers and government contractors, with a strategic focus on North American markets. The company also maintains strategic partnerships, such as with Benuvia Operations LLC, to leverage its manufacturing facilities for producing pharmaceutical-grade raw materials, positioning itself as a key provider in the federally authorized medicinal cannabis and pharmaceutical supply chain. Through these developments, Bright Green consolidates its regulatory certifications and strengthens its operational footprint in the emerging federally compliant plant-based drug sector.
Lynn Stockwell and Bright Green Corporation File $3 Billion Lawsuit Against Rodey Law Firm and Attorneys’ Liability Assurance Society (ALAS) for Legal Malpractice and Bad Faith
Wedbush's Ives Sees 'Bright Green Light' for Tech Stocks
PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation “BGXXQ” Q and A
Bright Green Corporation Merges with PharmAGRI Capital Partners; Lynn Stockwell Appointed CEO and Chairwoman
Is Media And Entertainment A Growth Sector? These 3 Legacy Giants Are Flashing Bright Green
Bright Green Corporation Announces the next steps for the completion of its restructuring plan
Bright Green Corporation Announces the completion of its restructuring plan, withdraws from the Cannabis business and sets course on the production of all DEA Scheduled Controlled Substances
Bright Green Corporation Has Signed Agreement with Majority Shareholder as Plan Sponsor on Prepackaged Plan to Restructure the Company.
LYNN STOCKWELL ENTERS INTO A RESTRUCTURING SECURITY AGREEMENT (“RSA”) WITH BRIGHT GREEN CORPORATION AND ASSUMES THE ROLE OF EXECUTIVE CHAIR AND CEO.
Bright Green Corporation Provides an Update, Reinforces Commitment to Shareholders, and Focuses on Growth and Strategic Partnerships
BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA OPERATIONS, LLC. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.
BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.
BRIGHT GREEN ANNOUNCES IT HAS OBTAINED A $3.5 MILLION FUNDING COMMITMENT UNDER AN EXISTING LINE OF CREDIT AND HAS ENGAGED AN INVESTMENT BANK TO SEEK A $15.0 MILLION DEBT FINANCING TO MOVE FORWARD WITH COMMERCIALIZATION.
CEO UPDATE
BRIGHT GREEN ANNOUNCES ITS EXPANSION CONTINUATION WITH A $100 MILLION SOLAR POWERED GENERATION FIELD TO SUPPLY HEAT AND ELECTRICITY TO ITS DRUG PRODUCTION AND MANUFACTURING FACILITY.
BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF ITS CONTROLLED SUBSTANCES DRUG PRODUCTION FACILITY IN GRANTS, NEW MEXICO AND OBTAINS $60 MILLION IN FINANCING
Bright Green Corporation (BGXX) submits for historic DEA Registration for Production of Schedule I and Schedule II controlled substances.
BRIGHT GREEN CORPORATION GAINS MOMENTUM FOR THEIR “DRUGS MADE IN AMERICA” PLATFORM WITH APPROVAL FOR THE RESEARCH, PRODUCTION AND MANUFACTURING OF ALL SCHEDULE I AND SCHEDULE II PLANT-BASED DRUGS
BRIGHT GREEN CORPORATION ANNOUNCES CHANGES TO BOARD OF DIRECTORS
Bright Green Corporation announces the agreement to acquire platform technologies and associated intellectual property from C2 Wellness Corp.